The outcome of prophylactic intravenous cefazolin and ceftriaxone in cirrhotic patients at different clinical stages of disease after endoscopic interventions for acute variceal hemorrhage.

Antibiotic prophylaxis with norfloxacin, intravenous ciprofloxacin, or ceftriaxone has been recommended for cirrhotic patients with gastrointestinal hemorrhage but little is known about intravenous cefazolin. This study aimed to compare the outcome of intravenous cefazolin and ceftriaxone as prophyl...

Full description

Bibliographic Details
Main Authors: Cheng-Kun Wu, Jing-Houng Wang, Chen-Hsiang Lee, Keng-Liang Wu, Wei-Chen Tai, Sheng-Nan Lu, Tsung-Hui Hu, Seng-Kee Chuah
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3632526?pdf=render
id doaj-c7930f11825844338afe1f2f1a5746fc
record_format Article
spelling doaj-c7930f11825844338afe1f2f1a5746fc2020-11-25T01:22:44ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0184e6166610.1371/journal.pone.0061666The outcome of prophylactic intravenous cefazolin and ceftriaxone in cirrhotic patients at different clinical stages of disease after endoscopic interventions for acute variceal hemorrhage.Cheng-Kun WuJing-Houng WangChen-Hsiang LeeKeng-Liang WuWei-Chen TaiSheng-Nan LuTsung-Hui HuSeng-Kee ChuahAntibiotic prophylaxis with norfloxacin, intravenous ciprofloxacin, or ceftriaxone has been recommended for cirrhotic patients with gastrointestinal hemorrhage but little is known about intravenous cefazolin. This study aimed to compare the outcome of intravenous cefazolin and ceftriaxone as prophylactic antibiotics among cirrhotic patients at different clinical stages, and to identify the associated risk factors. The medical records of 713 patients with acute variceal bleeding who had received endoscopic procedures from were reviewed. Three hundred and eleven patients were entered for age-matched adjustment after strict exclusion criteria. After the adjustment, a total of 102 patients were enrolled and sorted into 2 groups according to the severity of cirrhosis: group A (Child's A patients, n = 51) and group B (Child's B and C patients, n = 51). The outcomes were prevention of infection, time of rebleeding, and death. Our subgroup analysis results failed to show a significant difference in infection prevention between patients who received prophylactic cefazolin and those who received ceftriaxone among Child's A patients (93.1% vs. 90.9%, p = 0.641); however, a trend of significance in favor of ceftriaxone prophylaxis (77.8% vs. 87.5%, p = 0.072) was seen among Child's B and C patients. More rebleeding cases were observed in patients who received cefazolin than in those who received ceftriaxone among Child's B and C patients (66.7% vs. 25.0%, p = 0.011) but not in Child's A patients (32% vs. 40.9%, p = 0.376). The risk factors associated with rebleeding were history of bleeding and use of prophylactic cefazolin among Child's B and C patients. In conclusion, this study suggests that prophylactic intravenous cefazolin may not be inferior to ceftriaxone in preventing infections and reducing rebleeding among Child's A cirrhotic patients after endoscopic interventions for acute variceal bleeding. Prophylactic intravenous ceftriaxone yields better outcome among Child's B and C patients.http://europepmc.org/articles/PMC3632526?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Cheng-Kun Wu
Jing-Houng Wang
Chen-Hsiang Lee
Keng-Liang Wu
Wei-Chen Tai
Sheng-Nan Lu
Tsung-Hui Hu
Seng-Kee Chuah
spellingShingle Cheng-Kun Wu
Jing-Houng Wang
Chen-Hsiang Lee
Keng-Liang Wu
Wei-Chen Tai
Sheng-Nan Lu
Tsung-Hui Hu
Seng-Kee Chuah
The outcome of prophylactic intravenous cefazolin and ceftriaxone in cirrhotic patients at different clinical stages of disease after endoscopic interventions for acute variceal hemorrhage.
PLoS ONE
author_facet Cheng-Kun Wu
Jing-Houng Wang
Chen-Hsiang Lee
Keng-Liang Wu
Wei-Chen Tai
Sheng-Nan Lu
Tsung-Hui Hu
Seng-Kee Chuah
author_sort Cheng-Kun Wu
title The outcome of prophylactic intravenous cefazolin and ceftriaxone in cirrhotic patients at different clinical stages of disease after endoscopic interventions for acute variceal hemorrhage.
title_short The outcome of prophylactic intravenous cefazolin and ceftriaxone in cirrhotic patients at different clinical stages of disease after endoscopic interventions for acute variceal hemorrhage.
title_full The outcome of prophylactic intravenous cefazolin and ceftriaxone in cirrhotic patients at different clinical stages of disease after endoscopic interventions for acute variceal hemorrhage.
title_fullStr The outcome of prophylactic intravenous cefazolin and ceftriaxone in cirrhotic patients at different clinical stages of disease after endoscopic interventions for acute variceal hemorrhage.
title_full_unstemmed The outcome of prophylactic intravenous cefazolin and ceftriaxone in cirrhotic patients at different clinical stages of disease after endoscopic interventions for acute variceal hemorrhage.
title_sort outcome of prophylactic intravenous cefazolin and ceftriaxone in cirrhotic patients at different clinical stages of disease after endoscopic interventions for acute variceal hemorrhage.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2013-01-01
description Antibiotic prophylaxis with norfloxacin, intravenous ciprofloxacin, or ceftriaxone has been recommended for cirrhotic patients with gastrointestinal hemorrhage but little is known about intravenous cefazolin. This study aimed to compare the outcome of intravenous cefazolin and ceftriaxone as prophylactic antibiotics among cirrhotic patients at different clinical stages, and to identify the associated risk factors. The medical records of 713 patients with acute variceal bleeding who had received endoscopic procedures from were reviewed. Three hundred and eleven patients were entered for age-matched adjustment after strict exclusion criteria. After the adjustment, a total of 102 patients were enrolled and sorted into 2 groups according to the severity of cirrhosis: group A (Child's A patients, n = 51) and group B (Child's B and C patients, n = 51). The outcomes were prevention of infection, time of rebleeding, and death. Our subgroup analysis results failed to show a significant difference in infection prevention between patients who received prophylactic cefazolin and those who received ceftriaxone among Child's A patients (93.1% vs. 90.9%, p = 0.641); however, a trend of significance in favor of ceftriaxone prophylaxis (77.8% vs. 87.5%, p = 0.072) was seen among Child's B and C patients. More rebleeding cases were observed in patients who received cefazolin than in those who received ceftriaxone among Child's B and C patients (66.7% vs. 25.0%, p = 0.011) but not in Child's A patients (32% vs. 40.9%, p = 0.376). The risk factors associated with rebleeding were history of bleeding and use of prophylactic cefazolin among Child's B and C patients. In conclusion, this study suggests that prophylactic intravenous cefazolin may not be inferior to ceftriaxone in preventing infections and reducing rebleeding among Child's A cirrhotic patients after endoscopic interventions for acute variceal bleeding. Prophylactic intravenous ceftriaxone yields better outcome among Child's B and C patients.
url http://europepmc.org/articles/PMC3632526?pdf=render
work_keys_str_mv AT chengkunwu theoutcomeofprophylacticintravenouscefazolinandceftriaxoneincirrhoticpatientsatdifferentclinicalstagesofdiseaseafterendoscopicinterventionsforacutevaricealhemorrhage
AT jinghoungwang theoutcomeofprophylacticintravenouscefazolinandceftriaxoneincirrhoticpatientsatdifferentclinicalstagesofdiseaseafterendoscopicinterventionsforacutevaricealhemorrhage
AT chenhsianglee theoutcomeofprophylacticintravenouscefazolinandceftriaxoneincirrhoticpatientsatdifferentclinicalstagesofdiseaseafterendoscopicinterventionsforacutevaricealhemorrhage
AT kengliangwu theoutcomeofprophylacticintravenouscefazolinandceftriaxoneincirrhoticpatientsatdifferentclinicalstagesofdiseaseafterendoscopicinterventionsforacutevaricealhemorrhage
AT weichentai theoutcomeofprophylacticintravenouscefazolinandceftriaxoneincirrhoticpatientsatdifferentclinicalstagesofdiseaseafterendoscopicinterventionsforacutevaricealhemorrhage
AT shengnanlu theoutcomeofprophylacticintravenouscefazolinandceftriaxoneincirrhoticpatientsatdifferentclinicalstagesofdiseaseafterendoscopicinterventionsforacutevaricealhemorrhage
AT tsunghuihu theoutcomeofprophylacticintravenouscefazolinandceftriaxoneincirrhoticpatientsatdifferentclinicalstagesofdiseaseafterendoscopicinterventionsforacutevaricealhemorrhage
AT sengkeechuah theoutcomeofprophylacticintravenouscefazolinandceftriaxoneincirrhoticpatientsatdifferentclinicalstagesofdiseaseafterendoscopicinterventionsforacutevaricealhemorrhage
AT chengkunwu outcomeofprophylacticintravenouscefazolinandceftriaxoneincirrhoticpatientsatdifferentclinicalstagesofdiseaseafterendoscopicinterventionsforacutevaricealhemorrhage
AT jinghoungwang outcomeofprophylacticintravenouscefazolinandceftriaxoneincirrhoticpatientsatdifferentclinicalstagesofdiseaseafterendoscopicinterventionsforacutevaricealhemorrhage
AT chenhsianglee outcomeofprophylacticintravenouscefazolinandceftriaxoneincirrhoticpatientsatdifferentclinicalstagesofdiseaseafterendoscopicinterventionsforacutevaricealhemorrhage
AT kengliangwu outcomeofprophylacticintravenouscefazolinandceftriaxoneincirrhoticpatientsatdifferentclinicalstagesofdiseaseafterendoscopicinterventionsforacutevaricealhemorrhage
AT weichentai outcomeofprophylacticintravenouscefazolinandceftriaxoneincirrhoticpatientsatdifferentclinicalstagesofdiseaseafterendoscopicinterventionsforacutevaricealhemorrhage
AT shengnanlu outcomeofprophylacticintravenouscefazolinandceftriaxoneincirrhoticpatientsatdifferentclinicalstagesofdiseaseafterendoscopicinterventionsforacutevaricealhemorrhage
AT tsunghuihu outcomeofprophylacticintravenouscefazolinandceftriaxoneincirrhoticpatientsatdifferentclinicalstagesofdiseaseafterendoscopicinterventionsforacutevaricealhemorrhage
AT sengkeechuah outcomeofprophylacticintravenouscefazolinandceftriaxoneincirrhoticpatientsatdifferentclinicalstagesofdiseaseafterendoscopicinterventionsforacutevaricealhemorrhage
_version_ 1725125705804546048